• Text Size:

  • Print:

  • Share:


Clinical Trials

Cardinoid Protocols

As of July 8, 2013 - protocols do open and close daily.  
Please check with your physician for additional protocols and/or information.


1. S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs. Depot Octreotide + Bevacizumab in Advanced Poor Prognosis Carcinoid Patients

The purpose of this study is to compare the effects, good and/or bad, of octreotide plus bevacizumab with octreotide plus interferon on you and your carcinoid tumor to find out which is better. In this study, you will get either the bevacizumab or the interferon. You will not get both. Interferon is considered an accepted treatment for carcinoid tumors. Octreotide is an accepted treatment for carcinoid tumor and is a standard treatment for carcinoid syndrome. The combination of octreotide and interferon is considered a standard option even for patients who have progressed on octreotide alone. Bevacizumab is considered experimental for treating patients with carcinoid tumors.

For more information on this protocol or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133

Orange Regional
Medical Center

707 East Main Street
Middletown, NY 10940
Directions »

Orange Regional Medical
Group - Middletown

707 East Main Street
Middletown, NY 10940

Orange Regional Medical
Group - Monroe

475 Route 17M
Monroe, NY 10950

For Medical Staff
For Employees
Join Our Email List
Disclaimer | Privacy Policy | Sitemap | Locations

Copyright © 2017 Orange Regional Medical Center
Joint Commission National Quality Approved
A member of the Greater Hudson Valley Health System